Semler Scientific, Inc. SMLR
We take great care to ensure that the data presented and summarized in this overview for Semler Scientific, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SMLR
View all-
Cerity Partners LLC New York, NY702KShares$16.4 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA319KShares$7.45 Million0.0% of portfolio
-
Black Rock Inc. New York, NY310KShares$7.24 Million0.0% of portfolio
-
Lsv Asset Management Chicago, IL253KShares$5.9 Million0.02% of portfolio
-
Acadian Asset Management LLC Boston, MA166KShares$3.87 Million0.02% of portfolio
-
Avalon Investment & Advisory Houston, TX133KShares$3.1 Million0.1% of portfolio
-
Geode Capital Management, LLC Boston, MA114KShares$2.66 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX107KShares$2.49 Million0.0% of portfolio
-
Jacobs Levy Equity Management, Inc Florham Park, NJ98.3KShares$2.29 Million0.01% of portfolio
-
State Street Corp Boston, MA91.3KShares$2.13 Million0.0% of portfolio
Latest Institutional Activity in SMLR
Top Purchases
Top Sells
About SMLR
Semler Scientific, Inc. provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. Its products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups. The company offers its products through salespersons and distributors. Semler Scientific, Inc. was incorporated in 2007 and is headquartered in Santa Clara, California.
Insider Transactions at SMLR
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 10
2024
|
William H Chang Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,182
+50.0%
|
-
|
|
May 10
2024
|
Eric Semler Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,182
+0.38%
|
-
|
|
May 10
2024
|
Daniel S Messina Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,182
+17.08%
|
-
|
|
Sep 13
2023
|
Eric Semler Director |
BUY
Open market or private purchase
|
Indirect |
26,868
+25.68%
|
$752,304
$28.11 P/Share
|
|
Sep 12
2023
|
Eric Semler Director |
BUY
Open market or private purchase
|
Indirect |
25,903
+33.73%
|
$699,381
$27.7 P/Share
|
|
Sep 11
2023
|
Eric Semler Director |
BUY
Open market or private purchase
|
Indirect |
25,000
+50.0%
|
$650,000
$26.98 P/Share
|
|
May 31
2023
|
Daniel S Messina Director |
BUY
Grant, award, or other acquisition
|
Direct |
909
+9.75%
|
-
|
|
Feb 01
2023
|
Daniel S Messina Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,045
+28.87%
|
-
|
|
Feb 01
2023
|
Wayne T Pan Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,436
+4.87%
|
-
|
|
Feb 01
2023
|
Arthur N Leibowitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,436
+33.37%
|
-
|
|
Feb 01
2023
|
Cindy Moon Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,071
-25.01%
|
$43,911
$41.05 P/Share
|
|
Feb 01
2023
|
Cindy Moon Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,436
+36.26%
|
-
|
|
Oct 20
2022
|
Daniel S Messina Director |
BUY
Grant, award, or other acquisition
|
Direct |
649
+12.71%
|
-
|
|
Jul 01
2022
|
Daniel S Messina Director |
BUY
Grant, award, or other acquisition
|
Direct |
871
+18.62%
|
-
|
|
Apr 01
2022
|
Daniel S Messina Director |
BUY
Grant, award, or other acquisition
|
Direct |
507
+14.73%
|
-
|
|
Feb 28
2022
|
Douglas Murphy Chutorian CEO |
SELL
Open market or private sale
|
Direct |
2,000
-55.66%
|
$146,000
$73.03 P/Share
|
|
Feb 28
2022
|
Douglas Murphy Chutorian CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
$4,000
$2.1 P/Share
|
|
Feb 22
2022
|
Douglas Murphy Chutorian CEO |
SELL
Open market or private sale
|
Direct |
2,000
-75.95%
|
$140,000
$70.23 P/Share
|
|
Feb 22
2022
|
Douglas Murphy Chutorian CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,000
+50.0%
|
$4,000
$2.1 P/Share
|
|
Feb 15
2022
|
Douglas Murphy Chutorian CEO |
SELL
Open market or private sale
|
Direct |
2,000
-55.37%
|
$152,000
$76.81 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 7.46K shares |
|---|---|
| Open market or private purchase | 77.8K shares |